Mednet Logo
HomeNeurologyQuestion

What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/steroids, etc.) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?

1
4 Answers
Mednet Member
Mednet Member
Medical Oncology · University of Chicago

Specifically, this seems to be a question around cilta-cel.

There has been some recent guidance to consider pre-emptively starting dexamethasone if the absolute lymphocyte count rises above 3,000 in the period following CAR T administration. This partially stems from the observation that many of the...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Winship Cancer Institute of Emory University

I don't think there is prospective data, and the SITC guidelines don't address this pertinent question.

As a group, we've discussed this, but have not settled on a standard yet.

One consideration is absolute lymphocyte count (ALC) monitoring in hopes of neurotoxicity mitigation:

  • Days 2-7 post CAR-T: ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

Excellent question @Dr. First Last and EXCELLENT thoughtful responses by @Dr. First Last and @Dr. First Last about how they are traversing this data-free zone. I will admit that we are using an ALC of 5000 cells/µL for our preemptive-dexamethasone cutoff at the moment and not 3000 cells/µL, except f...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Rheumatology · Ohio State University

I would consider prophylactic anti-IL1 blockade - like Ilaris, Acalyst, and anakinra. I think this could help a lot.

Park et al., Blood, 2023

Oliai et al., ASCO, 2021

Register or Sign In to see full answer